JP7258462B2 - Ｂ細胞悪性腫瘍の治療のためのセルデュラチニブ - Google Patents

Ｂ細胞悪性腫瘍の治療のためのセルデュラチニブ Download PDF

Info

Publication number
JP7258462B2
JP7258462B2 JP2017561821A JP2017561821A JP7258462B2 JP 7258462 B2 JP7258462 B2 JP 7258462B2 JP 2017561821 A JP2017561821 A JP 2017561821A JP 2017561821 A JP2017561821 A JP 2017561821A JP 7258462 B2 JP7258462 B2 JP 7258462B2
Authority
JP
Japan
Prior art keywords
composition
patient
mutation
selduratinib
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017561821A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018520117A (ja
JP2018520117A5 (enExample
Inventor
アンジャリ パンディー，
グレゴリー コフィー，
ジャネット リーズ，
Original Assignee
ポートラ ファーマシューティカルズ， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ポートラ ファーマシューティカルズ， エルエルシー filed Critical ポートラ ファーマシューティカルズ， エルエルシー
Publication of JP2018520117A publication Critical patent/JP2018520117A/ja
Publication of JP2018520117A5 publication Critical patent/JP2018520117A5/ja
Priority to JP2021108659A priority Critical patent/JP2021152076A/ja
Application granted granted Critical
Publication of JP7258462B2 publication Critical patent/JP7258462B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017561821A 2015-05-29 2016-05-27 Ｂ細胞悪性腫瘍の治療のためのセルデュラチニブ Active JP7258462B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021108659A JP2021152076A (ja) 2015-05-29 2021-06-30 Ｂ細胞悪性腫瘍の治療のためのセルデュラチニブ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562168530P 2015-05-29 2015-05-29
US62/168,530 2015-05-29
US201562263582P 2015-12-04 2015-12-04
US62/263,582 2015-12-04
PCT/US2016/034861 WO2016196385A1 (en) 2015-05-29 2016-05-27 Cerdulatinib for the treatment of b-cell malignancies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021108659A Division JP2021152076A (ja) 2015-05-29 2021-06-30 Ｂ細胞悪性腫瘍の治療のためのセルデュラチニブ

Publications (3)

Publication Number Publication Date
JP2018520117A JP2018520117A (ja) 2018-07-26
JP2018520117A5 JP2018520117A5 (enExample) 2019-06-20
JP7258462B2 true JP7258462B2 (ja) 2023-04-17

Family

ID=57441822

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017561821A Active JP7258462B2 (ja) 2015-05-29 2016-05-27 Ｂ細胞悪性腫瘍の治療のためのセルデュラチニブ
JP2021108659A Pending JP2021152076A (ja) 2015-05-29 2021-06-30 Ｂ細胞悪性腫瘍の治療のためのセルデュラチニブ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021108659A Pending JP2021152076A (ja) 2015-05-29 2021-06-30 Ｂ細胞悪性腫瘍の治療のためのセルデュラチニブ

Country Status (9)

Country Link
US (2) US20180147203A1 (enExample)
EP (1) EP3302485B1 (enExample)
JP (2) JP7258462B2 (enExample)
KR (1) KR102613106B1 (enExample)
CN (1) CN107683139A (enExample)
AU (1) AU2016270658B2 (enExample)
CA (1) CA2987324C (enExample)
ES (1) ES2958412T3 (enExample)
WO (1) WO2016196385A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170042896A1 (en) 2015-08-12 2017-02-16 Portola Pharmaceuticals, Inc. Cerdulatinib for treating myeloma
CN108367006B (zh) 2015-12-04 2021-12-31 博尔托拉制药公司 用于治疗血液癌症的赛度替尼
US20180065317A1 (en) 2016-09-06 2018-03-08 Cc3D Llc Additive manufacturing system having in-situ fiber splicing
WO2018189566A1 (en) * 2017-04-10 2018-10-18 Dorian Bevec Use of a chemical compound as a therapeutic agent
CN112074271B (zh) * 2018-05-04 2023-10-20 博尔托拉制药公司 用于治疗淋巴瘤的方法
JP7324778B2 (ja) 2018-05-04 2023-08-10 ポートラ ファーマシューティカルズ， エルエルシー セルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）の固体形態
TWI805751B (zh) 2018-05-04 2023-06-21 美商普托拉製藥有限公司 賽度替尼(cerdulatinib)之合成
CN108743947B (zh) * 2018-07-04 2020-12-15 复旦大学附属肿瘤医院 一种治疗b细胞淋巴瘤的药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011518158A (ja) 2008-04-16 2011-06-23 ポートラ ファーマシューティカルズ， インコーポレイテッド Ｓｙｋまたはｊａｋキナーゼ阻害剤としての２，６−ジアミノ−ピリミジン−５−イル−カルボキサミド
WO2014018567A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60255756A (ja) 1984-06-01 1985-12-17 Ikeda Mohandou:Kk アミノアルキルフエノキシ誘導体
WO1995032963A1 (en) 1994-06-01 1995-12-07 Yoshitomi Pharmaceutical Industries, Ltd. Thienylazole compound and thienotriazolodiazepine compound
WO1999031073A1 (en) 1997-12-15 1999-06-24 Yamanouchi Pharmaceutical Co., Ltd. Novel pyrimidine-5-carboxamide derivatives
WO2003037352A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. 1-phenyl-5-n-heterocyclyl-pyrazoles as cyclooxygenase inhibitors for the treatment of inflammation associated disorders
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CN1665789A (zh) 2002-06-28 2005-09-07 山之内制药株式会社 二氨基嘧啶酰胺衍生物
WO2008009458A1 (en) 2006-07-21 2008-01-24 Novartis Ag 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8367689B2 (en) 2009-05-06 2013-02-05 Portola Pharmaceuticals, Inc. Inhibitors of JAK
WO2012045010A1 (en) 2010-09-30 2012-04-05 Portola Pharmaceuticals, Inc. Combinations of 4-(3-(2h-1,2,3-triazo-2-yl) phenylamino)-2-((1r,2s)-2-aminocyclohexylamino) pyrimidine-5-carboxamide and fludarabine
HK1198579A1 (en) * 2011-08-10 2015-04-30 Novartis Pharma Ag Jak p13k/mtor combination therapy
CA2877903A1 (en) * 2012-06-27 2014-01-03 Novomer, Inc. Catalysts and methods for polyester production
US9676756B2 (en) 2012-10-08 2017-06-13 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
CA2890111A1 (en) 2012-11-02 2014-05-08 Pharmacyclics, Inc. Tec family kinase inhibitor adjuvant therapy
CN105282602A (zh) * 2014-07-07 2016-01-27 乐视致新电子科技（天津）有限公司 数据处理方法、装置及移动终端设备
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
US20170042896A1 (en) 2015-08-12 2017-02-16 Portola Pharmaceuticals, Inc. Cerdulatinib for treating myeloma
CN108367006B (zh) * 2015-12-04 2021-12-31 博尔托拉制药公司 用于治疗血液癌症的赛度替尼

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011518158A (ja) 2008-04-16 2011-06-23 ポートラ ファーマシューティカルズ， インコーポレイテッド Ｓｙｋまたはｊａｋキナーゼ阻害剤としての２，６−ジアミノ−ピリミジン−５−イル−カルボキサミド
WO2014018567A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ａ ｐｈａｓｅ Ｉ ｏｐｅｎ－ｌａｂｅｌ， ｍｕｌｔｉ－ｄｏｓｅ ｅｓｃａｌａｔｉｏｎ ｓｔｕｄｙ ｏｆ ｔｈｅ ｄｕａｌ Ｓｙｋ／Ｊａｋ ｉｎｈｉｂｉｔｏｒ ＰＲＴ０６２０７０ （ｃｅｒｄｕｌａｔｉｎｉｂ） ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｒｅｌａｐｓｅｄ／ｒｅｆｒａｃｔｏｒｙ Ｂ Ｃｅｌｌ ｍａｌｉｇｎａｎｃｉｅｓ，Ｂｌｏｏｄ，２０１４年，１２４ （２１），３１０３

Also Published As

Publication number Publication date
ES2958412T3 (es) 2024-02-08
EP3302485A1 (en) 2018-04-11
AU2016270658A1 (en) 2018-01-04
US20220096471A1 (en) 2022-03-31
CN107683139A (zh) 2018-02-09
KR102613106B1 (ko) 2023-12-12
EP3302485A4 (en) 2019-02-27
WO2016196385A1 (en) 2016-12-08
CA2987324C (en) 2023-08-22
KR20180011210A (ko) 2018-01-31
US12350269B2 (en) 2025-07-08
JP2018520117A (ja) 2018-07-26
EP3302485B1 (en) 2023-07-12
US20180147203A1 (en) 2018-05-31
JP2021152076A (ja) 2021-09-30
CA2987324A1 (en) 2016-12-08
AU2016270658B2 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
JP7258462B2 (ja) Ｂ細胞悪性腫瘍の治療のためのセルデュラチニブ
US11446300B2 (en) Cerdulatinib for treating hematological cancers
US10463671B2 (en) Combination therapy for treating cancer
CN112074271B (zh) 用于治疗淋巴瘤的方法
HK1253804B (en) Cerdulatinib for the treatment of b-cell malignancies
HK1253804A1 (en) Cerdulatinib for the treatment of b-cell malignancies
HK1262118A1 (en) Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma
HK1262118B (en) Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190516

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200317

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200917

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210630

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210630

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210707

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210708

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20210813

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20210817

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220907

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20221014

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20221019

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20230224

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20230322

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20230322

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230405

R150 Certificate of patent or registration of utility model

Ref document number: 7258462

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150